Targeted drug therapy in non-small cell lung cancer: Clinical significance and possible solutions-Part I
出版年份 2020 全文链接
标题
Targeted drug therapy in non-small cell lung cancer: Clinical significance and possible solutions-Part I
作者
关键词
-
出版物
Expert Opinion on Drug Delivery
Volume -, Issue -, Pages 1-30
出版商
Informa UK Limited
发表日期
2020-09-21
DOI
10.1080/17425247.2021.1825377
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations
- (2020) J. Mazieres et al. ANNALS OF ONCOLOGY
- KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?
- (2020) Misako Nagasaka et al. CANCER TREATMENT REVIEWS
- Mechanisms of resistance to pemetrexed in non-small cell lung cancer
- (2020) Jiaqi Liang et al. Translational Lung Cancer Research
- The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping
- (2020) Ravi Salgia et al. CANCER TREATMENT REVIEWS
- Brigatinib: Novel ALK Inhibitor for Non–Small-Cell Lung Cancer
- (2019) Sara A. Spencer et al. ANNALS OF PHARMACOTHERAPY
- TAS-120 Cancer Target Binding: Defining Reactivity and Revealing the First Fibroblast Growth Factor Receptor 1 (FGFR1) Irreversible Structure
- (2019) Maria Kalyukina et al. ChemMedChem
- Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies
- (2019) Fiona H Tan et al. OncoTargets and Therapy
- CDK4/6 inhibition alone and in combination for non-small cell lung cancer
- (2019) Jose Pacheco et al. Oncotarget
- Afatinib in non-small cell lung cancer with HER2 mutations: results of the prospective, open-label phase II NICHE trial of European Thoracic Oncology Platform (ETOP)
- (2019) Rafal Dziadziuszko et al. Journal of Thoracic Oncology
- Role of PD-L1 Expression in Non-Small Cell Lung Cancer and Their Prognostic Significance according to Clinicopathological Factors and Diagnostic Markers
- (2019) Konrad Pawelczyk et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Relevance of detection of mechanisms of resistance to ALK inhibitors in ALK-rearranged NSCLC in routine practice
- (2019) Philippe Jamme et al. Clinical Lung Cancer
- A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations
- (2019) Martin H. Voss et al. CLINICAL CANCER RESEARCH
- Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer
- (2019) J. Gao et al. Clinical & Translational Oncology
- HER2: defining a Neu target in non-small-cell lung cancer
- (2019) S Ekman ANNALS OF ONCOLOGY
- Outcome differences between first and second-generation EGFR inhibitors in advanced EGFR mutated NSCLC in a large population-based cohort
- (2019) Sally C. Lau et al. Clinical Lung Cancer
- ALK rearrangements: Biology, detection and opportunities of therapy in non-small cell lung cancer
- (2019) Gina Rosas et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- A phase I study of BOS172738 in patients with advanced solid tumors with RET gene alterations including non-small cell lung cancer and medullary thyroid cancer.
- (2019) Patrick Schoffski et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I/II multiple expansion cohort trial of MRTX849 in patients with advanced solid tumors with KRAS G12C mutation.
- (2019) Kyriakos P. Papadopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Early clinical experience with the pan-FGFR inhibitor rogaratinib in patients with non-small cell lung cancer selected based on FGFR mRNA expression levels.
- (2019) Markus Joerger et al. JOURNAL OF CLINICAL ONCOLOGY
- Emerging therapies for non-small cell lung cancer
- (2019) Chao Zhang et al. Journal of Hematology & Oncology
- Erdafitinib: First Global Approval
- (2019) Anthony Markham DRUGS
- Targeting ROS1 Rearrangements in Non-small Cell Lung Cancer: Crizotinib and Newer Generation Tyrosine Kinase Inhibitors
- (2019) Tessa A. Morris et al. DRUGS
- SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway–Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)
- (2019) Charu Aggarwal et al. Journal of Thoracic Oncology
- Enhanced efficacy of sitravatinib in metastatic models of antiangiogenic therapy resistance
- (2019) Melissa Dolan et al. PLoS One
- A Selective FGFR inhibitor AZD4547 suppresses RANKL/M-CSF/OPG-dependent ostoclastogenesis and breast cancer growth in the metastatic bone microenvironment
- (2019) Jinho Kang et al. Scientific Reports
- Intrinsic resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
- (2019) Santoni-Rugiu et al. Cancers
- Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study
- (2019) Gwo-Fuang Ho et al. BMC CANCER
- Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
- (2019) Alessandro Leonetti et al. BRITISH JOURNAL OF CANCER
- Crizotinib in MET deregulated or ROS1 rearranged pretreated non-small-cell lung cancer (METROS): a phase II, prospective, multicentre, two-arms trial
- (2019) Lorenza Landi et al. CLINICAL CANCER RESEARCH
- Enfortumab Vedotin, a fully human monoclonal antibody against Nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial Carcinoma
- (2019) Bradley A McGregor et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Capmatinib for the treatment of non-small cell lung cancer
- (2019) Johan Filip Vansteenkiste et al. Expert Review of Anticancer Therapy
- Systemic Therapy for Locally Advanced and Metastatic Non–Small Cell Lung Cancer
- (2019) Kathryn C. Arbour et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
- (2019) Akintunde Akinleye et al. Journal of Hematology & Oncology
- A Phase 2 Study of Lenvatinib in Patients With RET Fusion-Positive Lung Adenocarcinoma
- (2019) Toyoaki Hida et al. LUNG CANCER
- Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment
- (2019) Narjust Duma et al. MAYO CLINIC PROCEEDINGS
- TAS6417/CLN-081 Is a Pan-Mutation–Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations
- (2019) Hibiki Udagawa et al. MOLECULAR CANCER RESEARCH
- Targeted Therapy For RET-Rearranged Non-Small Cell Lung Cancer: Clinical Development And Future Directions
- (2019) Christoph Jakob Ackermann et al. OncoTargets and Therapy
- Response and acquired resistance to savolitinib in a patient with pulmonary sarcomatoid carcinoma harboring MET exon 14 skipping mutation: a case report
- (2019) Sen Han et al. OncoTargets and Therapy
- Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives
- (2019) Daniele Lavacchi et al. Drug Design Development and Therapy
- Targeting Oncogenic BRAF: Past, Present, and Future
- (2019) Zaman et al. Cancers
- BRAF Mutations Classes I, II, and III in NSCLC Patients Included in the SLLIP Trial: The Need for a New Pre-Clinical Treatment Rationale
- (2019) Jillian Wilhelmina Paulina Bracht et al. Cancers
- Epigenetic Mechanisms of Escape from BRAF Oncogene Dependency
- (2019) Khaliq et al. Cancers
- TRK inhibitors in TRK fusion-positive cancers
- (2019) A Drilon ANNALS OF ONCOLOGY
- 444PDSafety and preliminary clinical activity of repotrectinib in patients with advanced ROS1/TRK fusion-positive solid tumors (TRIDENT-1 study)
- (2019) A Drilon et al. ANNALS OF ONCOLOGY
- MO2-15-5Tepotinib in NSCLC patients with METex14 mutations: interim results from the phase II VISION study
- (2019) Hiroshi Sakai et al. ANNALS OF ONCOLOGY
- Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer
- (2019) A Amatu et al. ANNALS OF ONCOLOGY
- MEK Inhibitors in Lung Cancer—You Can Teach an Old Drug New Tricks
- (2019) Jonathan J. Havel CANCER RESEARCH
- OA02.02 Phase 1 Study of Safety, Tolerability, PK and Efficacy of AMG 510, a Novel KRASG12C Inhibitor, Evaluated in NSCLC
- (2019) R. Govindan et al. Journal of Thoracic Oncology
- P2.18-01 A Multicenter, Double-Blind, Randomized, Controlled Study of Bintrafusp Alfa (M7824) in Unresectable Stage III NSCLC
- (2019) E. Vokes et al. Journal of Thoracic Oncology
- P2.01-15 Phase II Single Arm Study of CABozantinib in Non-Small Cell Lung Cancer Patients with MET Deregulation (CABinMET)
- (2019) M. D'Arcangelo et al. Journal of Thoracic Oncology
- The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
- (2019) Jude Canon et al. NATURE
- EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma
- (2019) Maria Colombino et al. BMC Pulmonary Medicine
- Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy
- (2019) Zuan-Fu Lim et al. Journal of Hematology & Oncology
- A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation–Positive NSCLC Patients
- (2019) Giorgio Scagliotti et al. Journal of Thoracic Oncology
- Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1–2 study
- (2019) Myung-Ju Ahn et al. LANCET ONCOLOGY
- Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial
- (2019) Alice T Shaw et al. LANCET ONCOLOGY
- Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
- (2019) Robert C Doebele et al. LANCET ONCOLOGY
- Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer
- (2018) D E Gerber et al. ANNALS OF ONCOLOGY
- A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer
- (2018) Amita Patnaik et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Mechanisms of Resistance to PD-1 and PD-L1 Blockade
- (2018) Theodore S. Nowicki et al. CANCER JOURNAL
- HER2Deregulation in Lung Cancer: Right Time to Adopt an Orphan?
- (2018) Federico Cappuzzo et al. CLINICAL CANCER RESEARCH
- Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study
- (2018) Leora Horn et al. CLINICAL CANCER RESEARCH
- ALK inhibitors, resistance development, clinical trials
- (2018) J.M. Rothenstein et al. Current Oncology
- Antiangiogenic therapies in non-small-cell lung cancer
- (2018) A. Alshangiti et al. Current Oncology
- The side effects of platinum-based chemotherapy drugs: a review for chemists
- (2018) Rabbab Oun et al. DALTON TRANSACTIONS
- Glutathione metabolism in cancer progression and treatment resistance
- (2018) Ankita Bansal et al. JOURNAL OF CELL BIOLOGY
- KRAS -Mutant Non-Small Cell Lung Cancer: From Biology to Therapy
- (2018) Irene Ferrer et al. LUNG CANCER
- Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities
- (2018) Yazhuo Zhang et al. Molecular Cancer
- TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations
- (2018) Shinichi Hasako et al. MOLECULAR CANCER THERAPEUTICS
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- (2018) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Precision Targeted Therapy with BLU-667 for RET -Driven Cancers
- (2018) Vivek Subbiah et al. Cancer Discovery
- BRAF inhibitors in metastatic non-small cell lung cancer
- (2018) Geòrgia Anguera et al. Journal of Thoracic Disease
- Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors
- (2018) Dazhi Liu et al. Therapeutics and Clinical Risk Management
- OUP accepted manuscript
- (2018) ANNALS OF ONCOLOGY
- Crizotinib in patients (pts) with MET-amplified non-small cell lung cancer (NSCLC): Updated safety and efficacy findings from a phase 1 trial.
- (2018) D. Ross Camidge et al. JOURNAL OF CLINICAL ONCOLOGY
- Histone deacetylase 6 in cancer
- (2018) Ting Li et al. Journal of Hematology & Oncology
- The roles of metallothioneins in carcinogenesis
- (2018) Manfei Si et al. Journal of Hematology & Oncology
- Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study
- (2018) Fabrice Barlesi et al. LANCET ONCOLOGY
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
- (2018) Luis Paz-Ares et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting ROS1 rearrangements in non-small cell lung cancer with crizotinib and other kinase inhibitors
- (2018) Kartik Sehgal et al. Translational Cancer Research
- Drug Resistance in Non-Small Cell Lung Cancer: A Potential for NOTCH Targeting?
- (2018) Venus Sosa Iglesias et al. Frontiers in Oncology
- 1162PCemiplimab, a human monoclonal anti-PD-1, plus radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC): Results from a phase I expansion cohort (EC 2)
- (2018) V Moreno et al. ANNALS OF ONCOLOGY
- Activity of the Hsp90 inhibitor Luminespib Among Non-Small Cell Lung Cancers Harboring EGFR Exon 20 Insertions
- (2018) Z Piotrowska et al. ANNALS OF ONCOLOGY
- HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib
- (2018) Y Wang et al. ANNALS OF ONCOLOGY
- FGFR genes mutation is an independent prognostic factor and associated with lymph node metastasis in squamous non-small cell lung cancer
- (2018) Jing Jing Li et al. CANCER BIOLOGY & THERAPY
- Phase 1 Study of AMG 337, a Highly Selective Small-Molecule MET Inhibitor, in Patients With Advanced Solid Tumors
- (2018) David S. Hong et al. CLINICAL CANCER RESEARCH
- Necitumumab for the treatment of advanced non-small-cell lung cancer
- (2018) Asunción Díaz-Serrano et al. Future Oncology
- Anti-mitotic therapies in cancer
- (2018) Julia Tischer et al. JOURNAL OF CELL BIOLOGY
- Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
- (2018) Benjamin J Solomon et al. LANCET ONCOLOGY
- Sunitinib-suppressed miR-452-5p facilitates renal cancer cell invasion and metastasis through modulating SMAD4/SMAD7 signals
- (2018) Wei Zhai et al. Molecular Cancer
- NTRK fusion-positive cancers and TRK inhibitor therapy
- (2018) Emiliano Cocco et al. Nature Reviews Clinical Oncology
- CDK4/6 inhibition stabilizes disease in patients with p16-null non-small cell lung cancer and is synergistic with mTOR inhibition
- (2018) Priya K. Gopalan et al. Oncotarget
- Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer
- (2017) Erika Rijavec et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Selumetinib for the treatment of non-small cell lung cancer
- (2017) Francesca Casaluce et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- MEK inhibitors under development for treatment of non-small-cell lung cancer
- (2017) Chul Kim et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study
- (2017) Lucia Nogova et al. JOURNAL OF CLINICAL ONCOLOGY
- MA 12.01 A Phase Ib Study of the Combination of Afatinib and Ruxolitinib in EGFR Mutant NSCLC Progressed on EGFR-TKI: An Updated Analysis
- (2017) J.S. Park et al. Journal of Thoracic Oncology
- P2.06-024 Tedopi vs Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Advanced NSCLC Patients in a Phase 3, Randomized Trial: ATALANTE-1
- (2017) Benjamin Besse et al. Journal of Thoracic Oncology
- MA04.03 Preliminary Results of a Phase II Study about the Efficacy and Safety of Pyrotinib in Patients with HER2 Mutant Advanced NSCLC
- (2017) Shengxiang Ren et al. Journal of Thoracic Oncology
- Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non–Small Cell Lung Cancer
- (2017) Martin Reck et al. Journal of Thoracic Oncology
- MA04.02 Neratinib ± Temsirolimus in HER2-Mutant Lung Cancers: An International, Randomized Phase II Study
- (2017) Leena Gandhi et al. Journal of Thoracic Oncology
- Intracranial Activity of Cabozantinib in MET Exon 14–Positive NSCLC with Brain Metastases
- (2017) Samuel J. Klempner et al. Journal of Thoracic Oncology
- Recent Advances in Targeting ROS1 in Lung Cancer
- (2017) Jessica J. Lin et al. Journal of Thoracic Oncology
- P2.03b-016 Tesevatinib in NSCLC Patients with EGFR Activating Mutations and Brain Metastases (BM) or Leptomeningeal Metastases (LM)
- (2017) Davic Berz et al. Journal of Thoracic Oncology
- Dabrafenib plus trametinib in patients with previously untreated BRAF V600E -mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
- (2017) David Planchard et al. LANCET ONCOLOGY
- Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial
- (2017) Alice T Shaw et al. LANCET ONCOLOGY
- Management of ceritinib therapy and adverse events in patients with ALK -rearranged non-small cell lung cancer
- (2017) Raffaele Califano et al. LUNG CANCER
- The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable
- (2017) Thanyanan Reungwetwattana et al. LUNG CANCER
- Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence
- (2017) Biagio Ricciuti et al. MEDICAL ONCOLOGY
- Intra-tumor heterogeneity from a cancer stem cell perspective
- (2017) Pramudita R. Prasetyanti et al. Molecular Cancer
- Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes
- (2017) Alexander Drilon et al. Nature Reviews Clinical Oncology
- Tumour heterogeneity and resistance to cancer therapies
- (2017) Ibiayi Dagogo-Jack et al. Nature Reviews Clinical Oncology
- ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers
- (2017) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)
- (2017) Alexander Drilon et al. Cancer Discovery
- Targeting ALK: Precision Medicine Takes on Drug Resistance
- (2017) Jessica J. Lin et al. Cancer Discovery
- A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF -Mutant Colorectal Cancer
- (2017) Robin M.J.M. van Geel et al. Cancer Discovery
- Aberrant Signaling through the HER2-ERK1/2 Pathway is Predictive of Reduced Disease-Free and Overall Survival in Early Stage Non-Small Cell Lung Cancer (NSCLC) Patients
- (2017) Marianna Scrima et al. Journal of Cancer
- Optimal pembrolizumab dosing for non-small cell lung cancer: further studies still needed
- (2017) Hai-Yan Tu et al. Journal of Thoracic Disease
- Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape
- (2016) K. A. Olaussen et al. ANNALS OF ONCOLOGY
- Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboringRETrearrangement: a phase II clinical trial
- (2016) S.-H. Lee et al. ANNALS OF ONCOLOGY
- Crizotinib resistance: implications for therapeutic strategies
- (2016) I. Dagogo-Jack et al. ANNALS OF ONCOLOGY
- Fibroblast Growth Factor Receptor 1 Gene Amplification in Nonsmall Cell Lung Cancer
- (2016) Rui-Juan Liu et al. CHINESE MEDICAL JOURNAL
- Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations
- (2016) Gang G. Li et al. CLINICAL CANCER RESEARCH
- Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications
- (2016) A. Quintanal-Villalonga et al. DISEASE MARKERS
- The development of LOXO-195, a second generation TRK kinase inhibitor that overcomes acquired resistance to 1st generation inhibitors observed in patients with TRK-fusion cancers
- (2016) J. Blake et al. EUROPEAN JOURNAL OF CANCER
- Exon Skipping in theRETGene Encodes Novel Isoforms That Differentially Regulate RET Protein Signal Transduction
- (2016) Nicole A. Gabreski et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Clinicopathologic Features of Advanced Squamous NSCLC
- (2016) Mark A. Socinski et al. Journal of Thoracic Oncology
- HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers
- (2016) Bob T. Li et al. Journal of Thoracic Oncology
- FGFR Signaling as a Target for Lung Cancer Therapy
- (2016) Arpita Desai et al. Journal of Thoracic Oncology
- Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
- (2016) Heather Donaghy mAbs
- Targeting the KRAS Pathway in Non-Small Cell Lung Cancer
- (2016) P. Tomasini et al. ONCOLOGIST
- Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
- (2016) J. F. Gainor et al. Cancer Discovery
- Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application
- (2016) Young Kwang Chae et al. Oncotarget
- Nintedanib in NSCLC: evidence to date and place in therapy
- (2016) Giuseppe Bronte et al. Therapeutic Advances in Medical Oncology
- A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors
- (2015) A. W. Tolcher et al. ANNALS OF ONCOLOGY
- A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†
- (2015) G. R. Blumenschein et al. ANNALS OF ONCOLOGY
- Predictive value of STMN1 gene promoter polymorphism (−2166T>C) in patients with advanced NSCLC treated with the combination of platinum compounds and vinorelbine
- (2015) Radosław Mlak et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Lung Cancer in the Era of Precision Medicine
- (2015) K. Politi et al. CLINICAL CANCER RESEARCH
- Intratumoral Heterogeneity: From Diversity Comes Resistance
- (2015) A. Pribluda et al. CLINICAL CANCER RESEARCH
- Staging of lung cancer: the role of noninvasive, minimally invasive and invasive techniques
- (2015) Georgios Stamatis EUROPEAN RESPIRATORY JOURNAL
- Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies
- (2015) E. E. Evans et al. Cancer Immunology Research
- Nivolumab in NSCLC: latest evidence and clinical potential
- (2015) Raghav Sundar et al. Therapeutic Advances in Medical Oncology
- Managing treatment–related adverse events associated with Alk inhibitors
- (2014) J.M. Rothenstein et al. Current Oncology
- Reproducibility of Histopathological Diagnosis in Poorly Differentiated NSCLC: An International Multiobserver Study
- (2014) Erik Thunnissen et al. Journal of Thoracic Oncology
- Comprehensive molecular profiling of lung adenocarcinoma
- (2014) Eric A. Collisson et al. NATURE
- TRKing Down an Old Oncogene in a New Era of Targeted Therapy
- (2014) Aria Vaishnavi et al. Cancer Discovery
- Fibroblast growth factor signaling and inhibition in non-small cell lung cancer and their role in squamous cell tumors
- (2014) Ravi Salgia Cancer Medicine
- Ins and Outs of Kinase DFG Motifs
- (2013) Daniel K. Treiber et al. CHEMISTRY & BIOLOGY
- Trastuzumab emtansine: the first targeted chemotherapy for treatment of breast cancer
- (2013) Parvin F Peddi et al. Future Oncology
- Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells
- (2013) Erika Martinelli et al. INTERNATIONAL JOURNAL OF CANCER
- MEK and the inhibitors: from bench to bedside
- (2013) Akintunde Akinleye et al. Journal of Hematology & Oncology
- Lung Resistance Protein and Multidrug Resistance Protein in Non-Small Cell Lung Cancer and Their Clinical Significance
- (2013) ZJ Chen et al. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
- Programmed death ligand-1 expression in non-small cell lung cancer
- (2013) Vamsidhar Velcheti et al. LABORATORY INVESTIGATION
- EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics
- (2013) M. E. Arcila et al. MOLECULAR CANCER THERAPEUTICS
- Novel Targets in Non-Small Cell Lung Cancer: ROS1 and RET Fusions
- (2013) J. F. Gainor et al. ONCOLOGIST
- Role of Glutathione in Cancer Progression and Chemoresistance
- (2013) Nicola Traverso et al. Oxidative Medicine and Cellular Longevity
- Lung Cancer Screening with Low-Dose Computed Tomography
- (2013) Caroline Chiles RADIOLOGIC CLINICS OF NORTH AMERICA
- Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-targeted therapy for advanced non-small cell lung cancer: Molecular and clinical aspects
- (2012) Isamu Okamoto et al. CANCER SCIENCE
- Crizotinib for ALK-Rearranged Non-Small Cell Lung Cancer: A New Targeted Therapy for a New Target
- (2012) L. Gandhi et al. CLINICAL CANCER RESEARCH
- Ruxolitinib: The First FDA Approved Therapy for the Treatment of Myelofibrosis
- (2012) J. Mascarenhas et al. CLINICAL CANCER RESEARCH
- Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR/KRAS and Presence of PIK3CA/AKT1 Mutations
- (2012) N. Rekhtman et al. CLINICAL CANCER RESEARCH
- KRAS Mutations in Lung Cancer
- (2012) Niki Karachaliou et al. Clinical Lung Cancer
- The role of βIII-tubulin in non-small cell lung cancer patients treated by taxane-based chemotherapy
- (2012) Kyoichi Kaira et al. International Journal of Clinical Oncology
- Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome
- (2012) Nathan T. Ihle et al. JNCI-Journal of the National Cancer Institute
- Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
- (2012) Julian R. Molina et al. MAYO CLINIC PROCEEDINGS
- Epithelial Mesenchymal Transition in Drug Resistance and Metastasis of Lung Cancer
- (2012) Fariz Nurwidya et al. Cancer Research and Treatment
- The genetics and biology of KRAS in lung cancer
- (2012) Peter M. K. Westcott et al. Chinese Journal of Cancer
- Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer
- (2011) M. C. Garassino et al. ANNALS OF ONCOLOGY
- Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors
- (2011) C. M. Lovly et al. CANCER RESEARCH
- TP53 Mutations in Nonsmall Cell Lung Cancer
- (2011) Akira Mogi et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications
- (2011) Hiroyuki Yasuda et al. LANCET ONCOLOGY
- The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo
- (2011) J. Chen et al. MOLECULAR CANCER THERAPEUTICS
- Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer
- (2010) H. J. Ross et al. CLINICAL CANCER RESEARCH
- A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
- (2010) E. B. Haura et al. CLINICAL CANCER RESEARCH
- Side-Effects of Long-Term Administration of Erlotinib in Patients with Non-small Cell Lung Cancer
- (2010) Annemarie Becker et al. Journal of Thoracic Oncology
- Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC
- (2010) Alex Chang LUNG CANCER
- Bevacizumab
- (2010) F. Kazazi-Hyseni et al. ONCOLOGIST
- Semaphorin signaling in cancer cells and in cells of the tumor microenvironment - two sides of a coin
- (2009) L. Capparuccia et al. JOURNAL OF CELL SCIENCE
- The basics of epithelial-mesenchymal transition
- (2009) Raghu Kalluri et al. JOURNAL OF CLINICAL INVESTIGATION
- Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
- (2009) Neil L. Spector et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine
- (2008) J Souglakos et al. BRITISH JOURNAL OF CANCER
- Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: A systematic review of randomized controlled trials
- (2007) Anand Rajeswaran et al. LUNG CANCER
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now